Drugs and FDA
FDA approves Gazyva for adults with primary membranous nephropathy
The FDA approved obinutuzumab for proteinuria remission in adults with primary membranous nephropathy at risk for disease progression.

The FDA approved obinutuzumab, sold as Gazyva, for proteinuria remission in adults with primary membranous nephropathy who are at risk for disease progression, Healio reported. The FDA said it is the first drug approved for adults with the condition.
The approval was based on the phase 3 MAJESTY trial, which randomly assigned 142 adults to obinutuzumab or tacrolimus. At week 104, 36% of patients receiving obinutuzumab had complete proteinuria remission, compared with 6% receiving tacrolimus, according to the FDA.
The most common adverse effects in the trial were infusion-related reactions and upper respiratory tract infection. Obinutuzumab carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.


